Cambridge Antibody and Dyax expand phage display license.Cambridge Cambridge, city, Canada Cambridge (kām`brĭj), city (1991 pop. 92,772), S Ont., Canada, on the Grand River, NW of Hamilton. It was formed in 1973 with the amalgamation of Galt, Hespeler, and Preston, all founded in the early 19th cent. Antibody antibody, protein produced by the immune system (see immunity) in response to the presence in the body of antigens: foreign proteins or polysaccharides such as bacteria, bacterial toxins, viruses, or other cells or proteins. Technology (Cambridge, England England, the largest and most populous portion of the United Kingdom of Great Britain and Northern Ireland (1991 pop. 46,382,050), 50,334 sq mi (130,365 sq km). It is bounded by Wales and the Irish Sea on the west and Scotland on the north. ) and Dyax Corporation (Cambridge, MA) announce an agreement to expand access and freedom to operate under each other's phage display phage display n. A technique using recombinant DNA technology to create bacteriophages with a desired peptide embedded in the surface of their protein shells. patents. This agreement expands upon those reached in 1997 under which Dyax licensed its Ladner Ladner may refer to: People
In addition, Cambridge Antibody's obligation to pay royalties under the 1997 Agreements to Dyax for rights with respect to Dyax's Ladner patents on antibody products Cambridge Antibody develops is removed, except in relation to Humira. Cambridge Antibody has options to buy out under a predetermined pre·de·ter·mine v. pre·de·ter·mined, pre·de·ter·min·ing, pre·de·ter·mines v.tr. 1. To determine, decide, or establish in advance: schedule any royalty obligation which Cambridge Antibody may have in respect of Humira. Peter Chambre, Cambridge Antibody's Chief Executive Officer, commented, "We are delighted to have reached this agreement with Dyax and are particularly pleased with the associated reduction in Cambridge Antibody's royalty burden. Importantly also the agreement enables Cambridge Antibody to share in Dyax' success as it develops products under the license in the future. This agreement is further evidence of Cambridge Antibody's commitment to licensing its phage phage: see bacteriophage. phage - A program that modifies other programs or databases in unauthorised ways; especially one that propagates a virus or Trojan horse. See also worm, mockingbird. The analogy, of course, is with phage viruses in biology. antibody patent portfolio; it is the third patent licensing agreement we have executed in the last month." Jack Morgan Morgan, American family of financiers and philanthropists. Junius Spencer Morgan, 1813–90, b. West Springfield, Mass., prospered at investment banking. , Senior Vice President of Dyax, commented: "We believe this agreement will expand pharmaceutical and biotechnology companies' access to state-of-the-art technology and ultimately benefit patients by facilitating expanded discoveries utilizing antibody phage display. This represents the fourth and most important patent cross licensing agreement Dyax has entered into over the past ten months. We are particularly excited to utilize the options to develop therapeutic antibodies for both Dyax's pipeline and for our customers." Cambridge Antibody Technology +44-1223-471-471 Dyax Corporation +1-617-250-5762 |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion